echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Hengrui PD-L1 monoanti-combination therapy has been approved for clinical use in a wide range of small cell lung cancer.

    Hengrui PD-L1 monoanti-combination therapy has been approved for clinical use in a wide range of small cell lung cancer.

    • Last Update: 2020-08-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On December 24, CDE's website showed that Hengrui SHR-1316 injections were clinically implied, combined with caropherin and endocoside for initial treatment of a wide range of small cell lung cancer patients.

    . SHR-1316 is a PD-L1 monoanti-drug developed by Heng Rui, which can relieve the immunosuppressive effect of PD-L1 mediated, enhance the function of lethal T cells, and play the role of mobilizing the body's immune system to remove tumor cells from the body.
    next Pharma, the pharmaceutical Rubik's Cube database, the current foreign-listed SHR-1316 are Roche's Tecentriq, Pfizer/Merck's Bavencio and AstraZenic's Imfinzi.
    2018, total global sales of these three products will be approximately $1,456 million. on December 9,
    , AstraZeneca Imfinzi was approved by the State Drug Administration for the treatment of non-removable stage III non-small cell lung cancer, which did not progress after simultaneous chemotherapy, and the product was called Infeifan (see: The first PD-L1 monotonica was approved in China!). Stage III lung cancer treatment ushered in a heavy weapon).
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.